Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Neoadjuvant chemoimmunotherapy has achieved high downstaging and pathologic response rates in nonsmall-cell lung cancer (NSCLC), but outcomes vary significantly. Early identification of beneficiaries remains a challenge.
Methods: This study analyzed baseline transcriptomic data from 24 NSCLC patients (9 major pathological response [MPR], 15 nonmajor pathological response [NMPR]) treated with neoadjuvant chemoimmunotherapy, sourced from the GEO database. Molecular analyses and immune infiltration analyses were performed using pathologic response as an endpoint. After identifying the interferon signaling subset NeoIGS, we analyzed the relationship between NeoIGS and immune scores, immune cell infiltration, and immunotherapy efficacy. A key gene in NeoIGS was screened by reveiver operating characteristic curve (ROC) analysis. Subsequently, the expression of the key gene was assessed by immunohistochemistry in 53 NSCLC patients receiving neoadjuvant chemoimmunotherapy.
Results: Interferon signaling pathway expression and CD8+ T-cell infiltration were higher in the MPR group. NeoIGS predicted pathological response to neoadjuvant chemoimmunotherapy (AUC = 0.926) and also demonstrated predictive value in the ICIs monotherapy cohort. IPS and TIDE scores also confirmed NeoIGS's association with immunotherapy in the TCGA NSCLC dataset. Furthermore, patients with higher NeoIGS scores had more immune cell infiltration and increased expression of ICI targets. ROC analysis identified ATF3 as NeoIGS's key gene. In the clinical cohort, ATF3 outperformed PD-L1 in predicting pathologic response, with a 90.0% MPR rate in the high-expression group.
Conclusion: We established that a subset of interferon signaling pathways, NeoIGS, is closely associated with immunotherapy. Among them, ATF3 is the most critical gene that accurately predicts pathological remission in neoadjuvant chemoimmunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994479 | PMC |
| http://dx.doi.org/10.1111/1759-7714.70056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al.
J Thorac Oncol
September 2025
Thoracic Surgery Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. Electronic address:
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.
ESMO Open
September 2025
Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.
Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.
Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017-2025.
Thorax
September 2025
University College London, London, UK.
Curative-intent multimodality treatment-combining local treatments such as surgery or radiotherapy with systemic therapy-is the cornerstone of care in stage II-III non-small cell lung cancer (NSCLC). Since 2017, the systemic therapy backbones with multimodality treatment have undergone a dramatic transformation, driven by a series of pivotal, practice-changing clinical trials. Immunotherapy and targeted therapies, previously confined to the advanced/metastatic setting, are now firmly embedded in curative-intent regimens.
View Article and Find Full Text PDFCurrent practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study.
Histopathology
September 2025
Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany.
Background: Given that pathologists now frequently assess pathologic response following neoadjuvant or perioperative chemoimmunotherapy for NSCLC, we set up a multicentre study to evaluate the current practice of regression grading in Germany (Re-GraDE NSCLC).
Methods: 133 cases of NSCLC resection specimens following chemoimmunotherapy (IO) were collected from 9 high-volume lung cancer centres in Germany. Case characteristics were obtained from pathology reports/electronic medical records.
Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer.
Clin Lung Cancer
August 2025
Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, China. Electronic address:
Background: Neoadjuvant chemotherapy plus anti-programmed death (ligand)-1 (anti-PD-(L)1) inhibitors (chemoimmunotherapy) for early-stage nonsmall cell lung cancer (NSCLC) is under investigation, but differences in pathological response rates between patients who achieved objective responses after 2 versus 3-6 cycles remain unclear.
Methods: We retrospectively enrolled 481 stage II-III NSCLC patients who had 2-6 cycles of neoadjuvant chemoimmunotherapy followed by surgery (June 2018-February 2024). The primary outcomes compared the pathological response (pathological complete response [pCR] and major pathological response [MPR]) between the 2-cycle (n = 99) and 3-6-cycle (n = 382) groups in patients who achieved objective response as well as between objective response rate (ORR) and non-ORR groups.